The female:male ratio is about 3:1 in MS. Overall, men and women tend to reach disability milestones at a similar age, despite numerous differences in the disease course. For example, men tend to be older at diagnosis, have more often a progressive onset of MS, have a lower relapse rate (with a greater proportion of motor relapses), and experience more rapid disability progression in relapsing-onset MS. In women, the risk of developing adverse health outcomes is nearly doubled compared with men. After menopause, women may experience increased disability progression, but also less inflammatory activity. Many gaps in scientific knowledge surround postmenopausal women, including the unknown effectiveness of hormone supplementation in stabilising symptoms or even offering neuroprotection.
Drug volume of distribution, metabolism, and elimination are likely to be influenced by sex differences in anatomy, body composition, and physiology. Despite known differences, most drugs have had no sex-specific dosage recommendations in their labels.
In the major clinical trials, evaluation of sex differences in enrolment characteristics, DMT efficacy, and/or side effects are incomplete. Dr Bove described in detail a study she recently published, reporting sex differences in a total of 29 clinical MS trials of DMT [2]. She found that:
- 0 of 29 trials reported baseline comparison of demographic or clinical characteristics according to sex;
- 10 of 29 trials reported a pre-planned analysis of efficacy based on sex (but without evaluating baseline sex differences);
- 0 of 29 trials performed a pre-planned analysis of major adverse events based on sex;
- 8 of 29 trials published post-hoc comparisons of sex differences in efficacy and safety outcomes; and
- 0 of 29 trials commented on statistical power to report sex differences.
Dr Bove also stressed that adjusting for sex differences is not the same as evaluating and understanding these differences. She would recommend at a minimum the following steps for reporting sex differences in future trials:
- giving attention to statistical power and pharmacokinetics/pharmacodynamics;
- harmonisation of baseline characteristics;
- evaluation of efficacy and safety; and
- consideration of sex-specific experiences or risks.
Ethical concerns complicate proper research in the area of pregnancy and lactation, but it could also be argued that it is the status quo which is “unethical”. An example of an ethical approach in research is to evaluate transfer of DMT into breast milk without exposing the infant. Obviously, DMT selection in women of childbearing potential is very important, including the issue of whether and when to discontinue a DMT, and how to avoid rebound risk. Dr Bove added that there is mounting evidence that B cell-depleting agents support disease control surrounding pregnancy, as B cell depletion can extend well beyond drug elimination.
- Bove R. Gender Based Approach to MS Therapeutics. MSVirtual 2020, Abstract PS12.01.
- Houtchens MK & Bove R. Front Neuroendocrinol. 2018;50:123-34.
Posted on
Previous Article
« Disease activity during pregnancy in a modern MS cohort Next Article
Clinical features of a recently identified disease: GFAP autoimmunity »
« Disease activity during pregnancy in a modern MS cohort Next Article
Clinical features of a recently identified disease: GFAP autoimmunity »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
August 18, 2021
Positive results from ublituximab versus teriflunomide
September 10, 2020
Imaging to evaluate remyelination and neuroprotection
November 5, 2020
Ocrelizumab benefits maintained in primary progressive MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com